HCPLive

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Most Popular

Recommended Reading

According to a new report, 15.6 million cosmetic procedures, including both minimally-invasive and surgical, were performed in the United States in 2014, an increase of 3 percent since 2013. The report was issued by the American Society of Plastic Surgeons.
Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum, especially for those diagnosed at younger ages, according to research published online Feb. 19 in JAMA Oncology.
Weightlifting and exercise are beneficial in an educational group for breast cancer survivors, researchers from the University of Pennsylvania determined in a recent study.
In March 2014, the Society of Surgical Oncology Susan G. Komen for the Cure Symposium focused on the literature on the epidemiology, molecular pathology, and therapy considerations of triple-negative breast cancer. The Annals of Surgical Oncology has published a summary of this work ahead of print.
$vAR$